Hnub Nyoog Txog NAFLD: Kev Siv Cov Probiotics Raws Li Kev Pab Txhawb Kev Kho Mob Part 4
Jun 26, 2023
Cov ntaub ntawv (cont.)
107. Azad, MAK; Sarker, M.; ib. Li, T.; Yin, J. Probiotic Hom nyob rau hauv Modulation ntawm Gut Microbiota: Ib Txheej Txheem. BioMed Res. Int. Xyoo 2018, 1-8. [CrossRef]
Glycoside ntawm cistanche tuaj yeem ua rau muaj kev ua haujlwm ntawm SOD hauv plawv thiab daim siab cov ntaub so ntswg, thiab txo cov ntsiab lus ntawm lipofuscin thiab MDA hauv txhua cov ntaub so ntswg, tshem tawm ntau yam reactive oxygen radicals (OH-, H₂O₂, thiab lwm yam) thiab tiv thaiv DNA puas. los ntawm OH-radicals. Cistanche phenylethanoid glycosides muaj peev xwm tshem tawm cov dawb radicals, muaj peev xwm txo tau ntau dua li cov vitamin C, txhim kho cov haujlwm ntawm SOD hauv cov phev ncua, txo cov ntsiab lus ntawm MDA, thiab muaj qee yam kev tiv thaiv ntawm cov phev ua haujlwm. Cistanche polysaccharides tuaj yeem txhim kho kev ua haujlwm ntawm SOD thiab GSH-Px hauv erythrocytes thiab ntsws cov ntaub so ntswg ntawm cov nas senescent sim los ntawm D-galactose, nrog rau txo cov ntsiab lus ntawm MDA thiab collagen hauv lub ntsws thiab ntshav, thiab nce cov ntsiab lus ntawm elastin, muaj Cov nyhuv scavenging zoo ntawm DPPH, ncua lub sijhawm ntawm hypoxia hauv cov nas senescent, txhim kho cov haujlwm ntawm SOD hauv cov ntshav, thiab ncua lub physiological degeneration ntawm lub ntsws hauv kev sim cov nas nrog cellular morphological degeneration, kev sim tau pom tias Cistanche muaj peev xwm antioxidant zoo. thiab muaj peev xwm los ua ib qho tshuaj tiv thaiv thiab kho cov kab mob ntawm daim tawv nqaij laus. Nyob rau tib lub sijhawm, echinacoside hauv Cistanche muaj lub peev xwm tseem ceeb txhawm rau txhawm rau DPPH dawb radicals thiab muaj peev xwm tshem tawm cov pa oxygen reactive thiab tiv thaiv dawb radical-induced collagen degradation, thiab kuj muaj kev kho zoo ntawm thymine dawb radical anion puas.
108. Duncan, SH; Flint, HJ Probiotics thiab Prebiotics thiab Kev Noj Qab Haus Huv hauv Cov Neeg Laus. Maturitas 2013, 75, 44–50. [CrossRef] [PubMed]
109. Reid, G.; Yaj, J.; Sebulsky, MT; McCormick, JK Muaj peev xwm siv Probiotics hauv Kev Kho Mob. Clin. Microbiol. Rev. 2003, 16, 658–672. [CrossRef]
110. Sanklecha, M.; Verma, L.; Pai, UA; Mishra, S.; Maqsood, S.; Birla, A. Lactobacillus Rhamnosus GG Kev Ntsuam Xyuas hauv Mob Ntshav Qab Zib (LEAD): Kev Tshawb Fawb Kev Tshawb Fawb. Cureus 2022. [CrossRef]
111. Ishida, Y.; Nakamura, F.; Kanzato, H.; Sawada, D.; Hirata, H.; Nishimura, A.; Kev, O.; Fujiwara, S. Clinical Effects of Lactobacillus Acidophilus Strain L-92 on Perennial Allergic Rhinitis: Ib Ob-Dig Muag, Kev Tshawb Fawb Placebo. J. Dairy Sci. Xyoo 2005, 88, 527–533. [CrossRef]
112. Surawicz, CM; Elmer, GW; Speelman, P.; McFarland, LV; Chaw, J.; Van Belle, G. Kev Tiv Thaiv Kab Mob Ntshav Qab Zib los ntawm Saccharomyces boulardii: Kev Tshawb Fawb Txog Kev Tshawb Fawb. Gastroenterology 1989, 96, 981–988. [CrossRef]
113. Zhou, B.; Ib, J.; Shimada, T.; Liu, S.; Maeyama, K. Oral Administration ntawm Enterococcus faecalis FK-23 Tshem Tawm Th17 Cell Development thiab Attenuates Allergic Airway Responses in nas. Int. J. Mol. Med. 2012, 30, 248–254. [CrossRef]
114. Wang, I.-J.; Wang, J.-Y. Cov menyuam yaus uas muaj kab mob Atopic Dermatitis qhia kev kho mob tom qab kis Lactobacillus. Clin. Exp. Allergy 2015, 45, 779–787. [CrossRef] [PubMed]
115. Kim, JY; Kwon, JH; Ahn, SH; Li, SI; Han, YS; Choi, YO; Li, SY; Ahn, KM; Ji, GE Cov nyhuv ntawm Probiotic Mix (Bifidobacterium Bifidum, Bifidobacterium Lactis, Lactobacillus Acidophilus) hauv Kev Tiv Thaiv Kev Tiv Thaiv Eczema: Ob Qhov Muag, Randomized, Placebo-Controlled Trial. Pediatric Allergy Immunol. 2010, 21, e386–e393. [CrossRef]
116. Gaziano, R.; Sabbatini, S.; Roseletti, E.; Perito, S.; Monari, C. Saccharomyces Cerevisiae-Based Probiotics li Novel Antimicrobial Agents los tiv thaiv thiab kho qhov chaw mos kab mob. Pem hauv ntej. Microbiol. 2020, 11, 718. [CrossRef] [PubMed]
117. Homayouni, A.; Bastani, P. Ziyadi, S.; Mohammad-Alizadeh-Charandabi, S.; Ghalibaf, M.; Mortazavian, AM; Mehrabany, EV Cov teebmeem ntawm Probiotics ntawm Kev Rov Ua Dua ntawm Kab Mob Vaginosis: Kev Ntsuam Xyuas. J. Low. Genet. Daim ntawv. Dis. Xyoo 2014, 18, 79–86. [CrossRef] [PubMed]
118. Moludi, J.; Kafil, HS; Qaisar, SA; Gholizadeh, P.; Alizadeh, M.; ib. Vayghyan, HJ Effect of Probiotic Supplementation with the Calorie Restriction on Metabolic Endotoxemia, and Inflamation Markers in Coronary Artery Disease Patients: Ob Chav Dig Muag Placebo Controlled Randomized Clinical Trial. Nutr. J. 2021, 20, 47. [CrossRef] [PubMed]
119. Yaj, B.; Yog, Y.; Chen, Y.; Ding, M.; Li, B.; Vaj, L.; Wang, Q.; Stanton, C.; ib. Ross, RP; Zhao, J.; ua al. Lactobacillus Plantarum CCFM1143 Alleviates Chronic Diarrhea ntawm Inflamation Regulation and Gut Microbiota Modulation: Ib Ob Qhov Muag, Randomized, Placebo-Controlled Study. Pem hauv ntej. Immunol. 2021, 12, 746585. [CrossRef] [PubMed]
120. Gamallat, Y.; Meyias, A.; Kuugbee, ED; Hago, AM; Chivala, G.; Awadasseid, A.; Bamba, D.; Zhang, X.; Shang, X.; Luo, F.; ua al. Lactobacillus Rhamnosus Induced Epithelial Cell Apoptosis, Ameliorates Inflammation, thiab tiv thaiv txoj hnyuv loj hlob hauv tus qauv tsiaj. Biomed. Kws tshuaj. 2016, 83, 536–541. [CrossRef]
121. Kuugbee, ED; Shang, X.; Gamallat, Y.; Bamba, D.; Awadasseid, A.; Suliman, MA; Zang, S.; Ma, Y.; Chivala, G.; Xin, Y.; ua al. Cov qauv hloov hauv Microbiota los ntawm Probiotic Cocktail txhim kho lub plab Barrier thiab txo cov qog nqaij hlav ntawm TLR2 Kev Tshaj Tawm hauv cov nas qauv ntawm cov kab mob qog noj ntshav. khawb. Dis. Sci. 2016, 61, 2908–2920. [CrossRef]
122. Boudeau, J.; Glasser, A.-L.; Julien, S.; Colombel, J.-F.; Darfeuille-Michaud, A. Inhibitory Effect of Probiotic Escherichia Coli Strain Nissle 1917 on Adhesion to and Invasion of Intestinal Epithelial Cells by Adherent-Invasive, E. Coli Strains Isolated from Patients with Crohn's Disease: INHIBITORY 19 KEV PAB CUAM AIEC COLONIZATION. Khoom noj khoom haus. Pharmacol. Ther. 2003, 18, 45–56. [CrossRef]
123. Kelesidis, T.; Pothoulakis, C. Kev ua tau zoo thiab kev nyab xeeb ntawm Probiotic Saccharomyces boulardii rau kev tiv thaiv thiab kho mob plab hnyuv. Ther. Adv. Gastroenterol. 2012, 5, 111–125. [CrossRef]
124. Yan, F.; Li, N.; Sib, J.; Li, H.; Yog, Y.; Jiao, W.; Wang, N.; Nkauj, Y.; Hu, G.; Li, B. Lactobacillus Acidophilus Alleviates Hom 2 Mob Ntshav Qab Zib los ntawm Kev Tswj Cov Ntshav Qab Zib Hepatic, Lipid Metabolism thiab Gut Microbiota hauv nas. Food Funct. Xyoo 2019, 10, 5804–5815. [CrossRef]
125. Yaj, B.; Huang, Z.; Nws, Z.; Yog, Y.; Zhou, Y.; Ross, RP; Stanton, C.; ib. Zhang, H. Zhao, J.; Chen, W. Kev Tiv Thaiv Kev Tiv Thaiv ntawm Bifidobacterium Bifidum FSDJN7O5 thiab Bifidobacterium Breve FHNFQ23M3 ntawm kev mob plab tshwm sim los ntawm Enterotoxigenic Escherichia Coli. Food Funct. 2021, 12, 7271–7282. [CrossRef] [PubMed]
126. Sullivan, Å.; Bennet, R.; Viitanen, M.; Palmgren, A.-C.; Nord, CE Kev cuam tshuam ntawm Lactobacillus F19 ntawm plab hnyuv microflora hauv cov menyuam yaus thiab cov neeg laus thiab cuam tshuam rau Helicobacter Pylori Kab Mob. Microb. Ecol. Health Dis. 2002, 14, 17–21. [CrossRef]
127. Hlivak, P.; Odraska, J.; Ferencik, M.; ib. Ebringer, L.; ib. Jahnova, E.; Mikes, Z. Kev thov ib xyoos ntawm Probiotic Strain Enterococcus Faecium M-74 Txo cov roj (cholesterol) hauv cov ntshav. Bratisl Lek Listy 2005, 106, 67–72.
128. Pakdaman, MN; Udani, JK; Molina, JP; Shahani, M. Qhov Teebmeem ntawm DDS-1 Hom Lactobacillus ntawm Kev Kho Mob rau Lactose Intolerance - Randomized, Ob-Dig Muag, Placebo-Controlled, Crossover Clinical Trial. Nutr. J. 2015, 15, 56. [CrossRef] [PubMed]
129. Lata, J.; Novotny, I.; Pˇríbramská, V.; Juranková, J.; Friˇc, P.; Khob, R.; Stib ˚urek, O. Cov txiaj ntsig ntawm Probiotics ntawm Gut Flora, Qib Endotoxin thiab Me Nyuam-Pugh Score hauv Cov Neeg Mob Cirrhotic: Cov txiaj ntsig ntawm Kev Tshawb Fawb Ob-Dig Muag Randomized. Eur. J. Gastroenterol. Hepatol. 2007, 19, 1111–1113. [CrossRef] [PubMed]
130. Lunia, MK; Sharma, BC; Sharma, P. Sachdeva, S.; Srivastava, S. Probiotics Tiv thaiv kab mob siab Encephalopathy nyob rau hauv cov neeg mob uas muaj cirrhosis: Ib tug randomized tswj kev sim. Clin. Gastroenterol. Hepatol. 2014, 12, 1003–1008.e1. [CrossRef]
131. Zhu, G.; Mas, F.; Wang, G.; Wang, Y.; Zhao, J.; Zhang, H. Chen, W. Bifidobacteria Attenuate txoj kev loj hlob ntawm Metabolic Disorders, nrog Inter- thiab Intra-Species txawv. Food Funct. 2018, 9, 3509–3522. [CrossRef]
132. Sohn, M.; Na, GY; Chu, J.; Yog, H.; Kim, B.K.; Lim, S. Kev ua tau zoo thiab kev nyab xeeb ntawm Lactobacillus Plantarum K50 ntawm Lipids hauv Kaus Lim Qab Teb nrog Kev rog: Ib qho Randomized, Ob-Dig Muag Tswj Kev Kho Mob. Pem hauv ntej. Endocrinol. 2022, 12, 790046. [CrossRef]
133. Anukam, KC; Hais, K.; Summers, K.; Reid, G. Probiotic Lactobacillus Rhamnosus GR-1 thiab Lactobacillus Reuteri RC-14 tuaj yeem pab txo qis TNF-Alpha, IL-6, IL-8, IL{6}} thiab IL-12 (P70) nyob rau hauv Neurogenic Bladder ntawm Spinal Cord Injured Patient with Urinary Tract Infections: A Ob-Case Study. Adv. Urol. 2009, 2009, 1–5. [CrossRef]
134. Sivamaruthi, BS; Kesika, P.; Chaiyasut, C. Kev tshuaj xyuas txog kev tiv thaiv kev laus ntawm probiotics. Int. J. App. Pharm. 2018, 10, 23. [CrossRef]
135. Salazar, N.; Valdés-Varela, L. González, S.; Gueimonde, M.; de los Reyes-Gavilán, CG Nutrition thiab Gut Microbiome hauv Cov Laus. Gut Microbes 2017, 8, 82–97. [CrossRef] [PubMed]
136. Lahtinen, SJ; Tammela, L.; Korpela, J.; Parhiala, R.; Ahokoski, H.; Mykkänen, H.; Salminen, SJ Probiotics Modulate Bifidobacterium Microbiota ntawm Cov Neeg Laus Hauv Tsev Laus. Xyoo 2009, 31, 59–66. [CrossRef] [PubMed]
137. Rampelli, S.; Candela, M.; ib. Severgnini, M. Biagi, E.; Turroni, S.; Roseli, M.; Carnevali, P.; Donini, L.; ib. Brigidi, P. A ProbioticsContaining Biscuit Modulates Intestinal Microbiota in the Elderly. J. Nutr. Health Aging 2013, 17, 166–172. [CrossRef] [PubMed]
138. Valentini, L.; ib. Pinto, A.; Bourdel-Marchasson, I.; Ostan, R.; Brigidi, P.; Turroni, S.; Hrelia, S.; Hrelia, P.; Bereswill, S.; Fischer, A.; ua al. Kev cuam tshuam ntawm Kev Noj Qab Haus Huv thiab Kev Noj Qab Haus Huv ntawm Tus Kheej thiab Kev Noj Qab Haus Huv Kev Noj Qab Haus Huv ntawm Kev Mob, Kev Noj Qab Haus Huv tsis zoo thiab plab hnyuv microbiota - "RISTOMED Project": Randomized Controlled Trial in Healthy Older. Clin. Nutr. 2015, 34, 593–602. [CrossRef]
139. Ahmed, M.; ib. Prasad, J.; Gill, H.; Stevenson, L.; ib. Gopal, P. Kev cuam tshuam ntawm kev noj cov qib sib txawv ntawm Bifidobacterium Lactis HN019 ntawm lub plab hnyuv microflora ntawm cov neeg laus cov ntsiab lus. J. Nutr. Health Aging 2007, 11, 26–31.
140. Azad, MAK; Sarker, M.; ib. Wan, D. Immunomodulatory Effects of Probiotics on Cytokine Profiles. BioMed Res. Int. 2018, 2018, 8063647. [CrossRef]
141. María Remes-Troche, J.; Coss-Adam, E.; Ángel Valdovinos-Díaz, M.; Gómez-Escudero, O.; Eugenia Icaza-Chavez, M.; Antonio Chavez-Barrera, J.; Zárate-Mondragón, F.; Antonio Velarde-Ruíz Velasco, J.; Rafael Aceves-Tavares, G.; Antonio Lira-Pedrín, M.; ua al. Lactobacillus Acidophilus LB: Ib Cov Tshuaj Siv Tau Zoo rau Kev Kho Mob plab. Ther. Adv. Gastroenterol. 2020, 13, 175628482097120. [CrossRef]
142. Sánchez, B.; Delgado, S.; Blanco-Míguez, A.; Lourenço, UA; Gueimonde, M.; Margolles, A. Probiotics, Gut Microbiota, thiab lawv qhov cuam tshuam rau tus tswv tsev noj qab haus huv thiab kab mob. Mol. Nutr. Khoom noj khoom haus Res. 2017, 61, 1600240. [CrossRef]
143. Hemarajata, P.; Versalovic, J. Cov teebmeem ntawm Probiotics ntawm Gut Microbiota: Mechanisms of Intestinal Immunomodulation and Neuromodulation. Ther. Adv. Gastroenterol. 2013, 6, 39–51. [CrossRef]
144. Chen, L.; ib. Li, H.; Li, J.; Chen, Y.; Yang, Y. Lactobacillus Rhamnosus GG Kev kho mob txhim kho plab hnyuv permeability thiab hloov kho Microbiota Dysbiosis hauv kev sim qauv ntawm Sepsis. Int. J. Mol. Med. 2019. [CrossRef] [PubMed]
145. Forsyth, CB; Farhadi, A.; Yog, SM; Tang, Y.; Shaikh, M.; Keshavarzian, A. Lactobacillus GG Kev Kho Mob Ameliorates AlcoholInduced plab hnyuv Oxidative Stress, plab Leakiness, thiab mob siab rau hauv tus nas qauv ntawm Cawv Steatohepatitis. Cawv 2009, 43, 163–172. [CrossRef] [PubMed]
146. Tao, Y.; Drabik, KA; Waypa, TS; Musch, MW; Alverdy, JC; Schneewind, O.; Chang, EB; Petrof, EO Soluble Factors los ntawm Lactobacillus GG Activate MAPKs thiab Induce Cytoprotective Heat Shock Proteins intestinal Epithelial Cells. Am. J. Physiol.-Cell Physiol. 2006, 290, C1018–C1030. [CrossRef] [PubMed]
147. Park, J.-S.; Choi, JW; Yim, J.; Kwon, JY; Li, B.-I.; Yang, CW; Park, S.-H.; Chaw, M.-L. Lactobacillus Acidophilus txhim kho txoj hnyuv plab hauv tus mob Colitis Mouse Model los ntawm Txoj Cai ntawm Th17 thiab Treg Cell Balance thiab Fibrosis Development. J. Med. Zaub mov 2018, 21, 215–224. [CrossRef]
148. Vemuri, R.; Shinde, T.; Gundamaraju, R.; Gondola, S.; Kev, A.; Beale, D.; Martoni, C.; Eri, R. Lactobacillus Acidophilus DDS-1 Modulates lub plab Microbiota thiab txhim kho metabolic Profiles hauv cov nas laus. Nutrients 2018, 10, 1255. [CrossRef]
149. Li, X.; Huang, Y.; Nkauj, L.; Xiao, Y.; Lu, S.; Xu, J.; Li, J.; Ren, Z. Lactobacillus Plantarum tiv thaiv kev rog dhau ntawm Modulation ntawm Gut Microbiota thiab Metabolites hauv High-Fat Feeding nas. J. Funct. Khoom noj khoom haus 2020, 73, 104103. [CrossRef]
150. Graziani, C.; Petio, V.; Del Chierico, F.; Mangiola, F.; Pecere, S.; Schiavoni, E.; Pizzoferrato, M.; Lopetuso, LR; Putignani, L.; Gasbarrini, UA; ua al. P115 Escherichia Coli Nissle 1917 Modulate Gut Microbiota Composition nyob rau hauv Ulcerative Colitis Cov Neeg Mob. J. Crohn's Colitis 2017, 11, S133–S134. [CrossRef]
151. Schlee, M.; Wehkamp, J.; Altenhoefer, A.; Oelschlaeger, TA; Stange, EF; Fellermann, K. Induction ntawm Tib Neeg -Defensin 2 los ntawm Probiotic Escherichia Coli Nissle 1917 Yog Mediated los ntawm Flagellin. Kab mob. Immun. 2007, 75, 2399–2407. [CrossRef]
152. Everard, A.; Matamoros, S.; Taus, L.; Delzenne, NM; Cani, PD Saccharomyces Boulardii Kev Tswj Xyuas Kev Hloov Pauv Microbiota thiab Txo Cov Kab Mob Hepatic Steatosis, Qeb Qeb Mob, thiab rog rog hauv rog thiab Hom 2 Mob Ntshav Qab Zib Db / Db nas. mBio 2014, 5, e01011–e01014. [CrossRef]
153. Grander, C.; Adolph, TE; Wieser, V.; Lov, P.; Wrzosek, L.; Gyongyosi, B.; Ward, DV; Grabherr, F.; Gerner, RR; Pfister, ib.; ua al. Rov qab ntawm Ethanol-Induced Akkermansia Muciniphila Depletion Ameliorates Alcoholic Liver Disease. Xyoo 2018, 67, 891–901. [CrossRef]
154. O'Toole, PW; Marchesi, JR; Hill, C. Next-Generation Probiotics: Lub Spectrum los ntawm Probiotics mus Nyob Biotherapeutics. Nat. Microbiol 2017, 2, 17057. [CrossRef] [PubMed]
155. Yao, M.; qw, l;. Lu, Y.; Wang, IB; Berglund, IB; Li, L. Kev Hloov Kho ntawm Kev Ua Tau Zoo thiab Kev Ua Haujlwm ntawm Probiotics rau Kev Kho Mob Ntshav Qab Zib Fatty Liver Disease. Engineering 2021, 7, 679–686. [CrossRef]
156. Roh, YS; Seki, E. Tus neeg txais xov tooj zoo li hauv Kab Mob Caw Li Cas, Tsis Muaj Cawv Steatohepatitis, thiab Carcinogenesis: Lub luag haujlwm ntawm TLR hauv ALD, NASH, thiab HCC. J. Gastroenterol. Hepatol. 2013, 28, 38–42. [CrossRef] [PubMed]
157. Wang, W.; Shi, LP; Sib, L.; Xu, L. Kev ua tau zoo ntawm probiotics ntawm kev kho mob ntawm cov kab mob uas tsis yog-alcoholic fatty siab. Zhonghua Nei Ke Za Zhi 2018, 57, 101–106. [CrossRef]
158. Wieland, A.; ib. Frank, DN; Harnke, IB.; Bambha, K. Kev tshuaj xyuas: Cov kab mob microbial dysbiosis thiab kab mob uas tsis yog-coholic fatty siab. Khoom noj khoom haus. Pharm. 2015, 42, 1051–1063. [CrossRef]
159. Mantovani, A.; Dalbeni, A. Kev Kho Mob rau NAFLD: Lub Xeev of Art. Int. J. Mol. Sci. 2021, 22, 2350. [CrossRef]
160. Borrelli, A.; ib. Bonelli, P. Tuccillo, FM; Goldfine, ID; Evans, JL; Buonaguro, FM; Mancini, A. Lub luag hauj lwm ntawm Gut Microbiota thiab Oxidative Stress nyob rau hauv kev loj hlob ntawm Non-Alcoholic Fatty Liver Disease mus rau Hepatocarcinoma: Tam sim no thiab Txoj Kev Kho Mob Tshiab. Redox Biol. 2018, 15, 467–479. [CrossRef] [PubMed]
161. Perumpail, B.; Li, A.; John, N.; Sallam, S.; Shah, N.; Kw, W.; Cholankeril, G.; Kim, D.; Ahmed, A. Txoj Kev Kho Mob ntawm Gut Microbiome thiab Probiotics hauv Cov Neeg Mob NAFLD. Kab mob 2019, 7, 27. [CrossRef] [PubMed]
162. Li, K.; Li, Y.; Wang, Y.; Wen, J.; Wu, H.; Yus, D.; Li, W. Cov nyhuv ntawm kev noj zaub mov ntxiv ntawm Bacillus Subtilis B10 ntawm Biochemical thiab Molecular Parameters nyob rau hauv cov ntshav thiab lub siab ntawm cov rog rog-Induced Obese nas. J. Zhejiang Univ. Sci. B 2015, 16, 487–495. [CrossRef]
163. Vajro, P.; Mandato, C.; Veropalumbo, C.; De Micco, I. Probiotics: Lub luag haujlwm muaj peev xwm hauv kev kho mob rau cov neeg laus thiab menyuam yaus uas tsis yog haus dej cawv fatty daim siab mob. Ann. Hepatol 2013, 12, 161–163. [CrossRef]
164. Li, C.; Nia, S.-P.; Zhu, K.-X.; Ding, Q.; Li, C.; Xiong, T.; Xie, M.-Y. Lactobacillus Plantarum NCU116 Txhim kho daim siab ua haujlwm, Oxidative Stress, thiab Lipid Metabolism hauv nas uas muaj roj ntau noj tsis haus cawv lossis haus cawv. Food Funct. 2014, 5, 3216–3223. [CrossRef] [PubMed]
165. Zhao, Z.; Wang, C.; Zhang, L. Zhao, Y.; Duan, C.; Zhang, X.; Gao, L.; Li, S. Lactobacillus Plantarum NA136 Txhim kho cov kab mob uas tsis yog-Alcoholic Fatty Liver Disease los ntawm Modulating AMPK/Nrf2 Pathway. Appl. Microbiol. Biotechnol. Xyoo 2019, 103, 5843–5850. [CrossRef]
166. Xin, J.; Zeng, D.; Wang, H.; Nia, X.; Yim, D.; Pan, K.; Jing, B. Tiv thaiv Tsis-Alcoholic Fatty Liver Disease los ntawm Lactobacillus Johnsonii BS15 los ntawm Attenuating Inflammation thiab Mitochondrial Injury thiab txhim kho plab ib puag ncig hauv cov nas rog rog. Appl. Microbiol. Biotechnol. Xyoo 2014, 98, 6817–6829. [CrossRef] [PubMed]
167. Ritze, Y.; Bardos, G.; Claus, A.; Ehrmann, V.; Bergheim, ib.; Schwiertz, UA; Bischoff, SC Lactobacillus Rhamnosus GG tiv thaiv cov kab mob uas tsis yog-Alcoholic Fatty Liver Disease hauv nas. PLoS IB 2014, 9, e80169. [CrossRef]
168. Ren, T.; Huang, C.; Cheng, M. Khoom noj khoom haus Blueberry thiab Bifidobacteria Attenuate Nonalcoholic Fatty Liver Disease nyob rau hauv nas los ntawm cuam tshuam SIRT1-Mediated Signaling Pathway. Oxidative Med. Cell. Longev. 2014, 2014, 1–12. [CrossRef] [PubMed]
169. Xu, R.; Wan, Y.; Fang, Q.; Lu, W.; Cai, W. Supplementation with Probiotics Modifies Gut Flora and Attenuates Liver Fat Accumulation in Rat Nonalcoh.holic Fatty Liver Disease Model. J. Clin. Biochem. Nutr. Xyoo 2011, 50, 72–77. [CrossRef] [PubMed]
170. Bubnov, RV; Babenko, LP; Lazarenko, LWM; Mokrozub, VV; Demchenko, UA; Nechypurenko, OV; Spivak, MY Comparative Study of Probiotic Effects of Lactobacillus thiab Bifidobacteria Strains on Cholesterol Levels, Liver Morphology and the Gut Microbiota in Obese nas. EPMA J. 2017, 8, 357–376. [CrossRef]
171. Xu, L.; Nws, J.; Gao, N.; Lu, X.; Li, M.; Wu, X.; Liu, Z.; Jin, Y.; Liu, J.; Xu, J.; ua al. Probiotics tuaj yeem ncua qhov kev loj hlob ntawm Nonalcoholic Fatty Liver Disease los ntawm Restoring Gut Microbiota Structure thiab txhim kho plab hnyuv endotoxemia. Sci. Rep. 2017, 7, 45176. [CrossRef]
172. Seo, M.; Ib, I.; Tanaka, M.; Matsuda, N.; Nakano, T.; Awata, T.; Katayama, S.; Alpers, DH; Komoda, T. Clostridium Butyricum MIYAIRI 588 Txhim kho Kev Noj Qab Haus Huv Kev Noj Qab Haus Huv-Induced Non-Alcoholic Fatty Liver Disease in nas. khawb. Dis. Sci. Xyoo 2013, 58, 3534–3544. [CrossRef]
173. Ma, X.; Hua, J.; Li, Z. Probiotics txhim kho cov rog rog uas ua rau lub siab ua rau lub siab Steatosis thiab Insulin Resistance los ntawm Kev Txhim Kho Kab Mob Siab NKT. J. Hepatol. 2008, 49, 821–830. [CrossRef]
174. Li, Z. Probiotics and Antibodies to TNF Inhibit Inflammatory Activity and Improve Nonalcoholic Fatty Liver Disease. Hepatology 2003, 37, 343–350. [CrossRef] [PubMed]
175. Munukka, E.; Rintala, UA; Toivonen, R.; Nylund, M.; Yaj, B.; Takanen, A.; Hänninen, UA; Vuopio, J.; Huovinen, P.; Jalkanen, S.; ua al. Faecalibacterium Prausnitzii Kev Kho Mob Txhim Kho Kab Mob Siab thiab txo cov kab mob adipose hauv cov nas uas muaj rog ntau. ISME J. 2017, 11, 1667–1679. [CrossRef] [PubMed]
176. Ahn, SB; Jun, DW; Kang, B.-K.; Lim, JH; Lim, S.; Chung, M.-J. Randomized, Ob-dig muag, Placebo-Controlled Study of a Multispecies Probiotic Mixture in Nonalcoholic Fatty Liver Disease. Sci Rep. 2019, 9, 5688. [CrossRef] [PubMed]
177. Chen, Y.; Feng, R.; Yang, X.; Dai, J.; Huang, M. Ji, X.; Li, Y.; Okekunle, AP; Gao, G.; Kev, JU; ua al. Yogurt Txhim Kho Insulin Resistance thiab Liver Fat nyob rau hauv cov poj niam rog rog nrog Nonalcoholic Fatty Liver Disease thiab Metabolic Syndrome: Ib qho Kev Sib Tham Randomized. Am. J. Clin. Nutr. 2019, 109, 1611–1619. [CrossRef]
178. Sepideh, A.; Karim, P.; Hossein, UA; Leila, R.; Hamdollah, M. Mohammad, EG; Mojtab, S.; Mohammad, S.; Ghader, G.; Seyed Moayed, A. Cov teebmeem ntawm Multistrain Probiotic Supplementation ntawm Glycemic thiab Inflammatory Indices nyob rau hauv cov neeg mob nrog Nonalcoholic Fatty Liver Disease: Ib Ob-Dig Muag Randomized Clinical Trial. J. Am. Col. Nutr. 2016, 35, 500–505. [CrossRef]
179. Aller, R.; De Luis, DA; Izaola, O.; Conde, R.; Gonzalez Sagrado, M. Primo, D.; De La Fuente, B. Gonzalez, J. Effect of a Probiotic on Liver Aminotransferases in Nonalcoholic Fatty Liver Disease Patients: Ob Chav Dig Muag Randomized Clinical Trial. Eur. Rev. Med. Pharm. Sci 2011, 15, 1090–1095.
180. Derosa, G.; Guas, L.; D'Angelo, UA; Martinotti, C.; Valentino, MC; Di Matteo, S.; Bruno, WM; Maresca, AM; Gaudio, GV; Maffioli, P. Probiotic Therapy with VSL#3®in Patients with NAFLD: Ib Randomized Clinical Trial. Pem hauv ntej. Nutr. 2022, 9, 846873. [CrossRef]
181. Shavakhi, A.; Minakari, M.; Firouzian, H.; Assali, R.; Hekmatdoost, A.; Ferns, G. Cov nyhuv ntawm Probiotic thiab Metformin ntawm daim siab Aminotransferases nyob rau hauv Non-Alcoholic Steatohepatitis: Ib Qhov Ob-Dig Muag Randomized Clinical Trial. Int. J. Prev. Med. 2013, 4, 531–537.
182. Kobyliak, N.; Abenavoli, L. Mykhalchyshyn, G.; Kononenko, L.; ib. Boccuto, L.; Kyrienko, D.; Dynnyk, O. A Multi-Strain Probiotic Txo Cov Fatty Liver Index, Cytokines thiab Aminotransferase Levels hauv NAFLD Cov Neeg Mob: Cov pov thawj los ntawm Randomized Clinical Trial. JGLD 2018, 27, 41–49. [CrossRef]
183. Mei, L.; Tang, Y.; Li, M.; Yaj, P.; Liu, Z.; Yuan, J.; Zheng, P. Co-Administration of Cholesterol-Lowering Probiotics and Anthraquinone from Cassia Obtusifolia, L. Ameliorate Non-Alcoholic Fatty Liver. PLoS IB 2015, 10, e0138078. [CrossRef]
184. Park, E.-J.; Li, Y.-S.; Kim, SM; Park, G.-S.; Li, YH; Yog, DY; Kang, J.; Li, H.J. Cov txiaj ntsig zoo ntawm Lactobacillus Plantarum Strains rau Cov Kab Mob Ntshav Qab Zib Fatty Liver Disease in High Fat/High Fructose Diet-Fed nas. Nutrients 2020, 12, 542. [CrossRef] [PubMed]
185. Yan, Y.; Liu, C.; Zhao, S.; Wang, X.; Wang, J.; Zhang, H. Wang, Y.; Zhao, G. Probiotic Bifidobacterium Lactis V9 Attenuates Hepatic Steatosis thiab Inflammation nyob rau hauv nas uas tsis yog-Alcoholic Fatty Liver Disease. AMB Expr. 2020, 10, 101. [CrossRef]
186. Nabavi, S.; Rafab, M.; Yim, MH; Homayouni-Rad, A.; Asghari-Jafarabadi, M. Cov txiaj ntsig ntawm Probiotic Yogurt Kev Noj Qab Haus Huv ntawm Metabolic Factors nyob rau hauv cov tib neeg uas tsis muaj dej cawv fatty siab kab mob. J. Dairy Sci. Xyoo 2014, 97, 7386–7393. [CrossRef] [PubMed]
187. Duseja, A.; Acharya, SK; Mas, M.; Chaw, S.; Shalimar, RS; Das, A.; Dattagupta, S.; Dhiman, RK; Chawla, YK High Potency Multistrain Probiotic Improves Liver Histology in Non-Alcoholic Fatty Liver Disease (NAFLD): Ib qho Randomised, Ob-Dig Muag, Pov Thawj ntawm Txoj Kev Kawm. BMJ Qhib Gastroenterol. Xyoo 2019, 6, e000315. [CrossRef] [PubMed]
188. Ma, J.; Zhou, Q. Li, H. Gut Microbiota thiab Nonalcoholic Fatty Liver Disease: Insights on Mechanisms and Therapy. Nutrients 2017, 9, 1124. [CrossRef]
189. Fianchi, F.; Liguori, A.; Gasbarrini, UA; Grieco, UA; Miele, L. Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut–Liver Axis Interaction: Los ntawm Pathphysiology mus rau Lub Hom Phiaj ntawm Kev Kho Mob rau Kev Kho Mob Tus Kheej. Int. J. Mol. Sci. 2021, 22, 6485. [CrossRef]
190. Gibson, GR; Roberfroid, MB Dietary Modulation ntawm Tib Neeg Colonic Microbiota: Qhia Txog Lub Tswv Yim ntawm Prebiotics. J. Nutr. 1995, 125, 1401–1412. [CrossRef]
191. Holscher, HD Dietary Fiber thiab Prebiotics thiab Gastrointestinal Microbiota. Gut Microbes 2017, 8, 172–184. [CrossRef]
192. de Vrese, M.; Schrezenmeir, J. Probiotics, Prebiotics, thiab Synbiotics. Food Biotechnology 2008, 111, 1–66.
193. Chambers, ES; Byrne, NWS; Morrison, DJ; Murphy, KG; Preston, T.; ib. Tedford, C.; Garcia-Perez, kuv.; Fontana, S.; SerranoContreras, JI; Holmes, E.; ua al. Kev noj zaub mov ntxiv nrog Inulin-Propionate Ester lossis Inulin Txhim Kho Insulin rhiab heev rau cov neeg laus uas rog dhau thiab rog nrog cov teebmeem tshwj xeeb ntawm lub plab Microbiota, Plasma Metabolome, thiab Cov Kab Mob Kab Mob: Ib qho kev sib tw hla dhau. Xyoo 2019, 68, 1430–1438. [CrossRef]
194. Tandon, D.; Haque, MM; Taus, M.; Yaj, M.; Bhaduri, A.; Dubey, AK; Mande, SS A Prospective Randomized, Ob-dig muag, Placebo-Controlled, Dose-Response Relationship Study los tshawb fawb txog kev ua tau zoo ntawm fructo-oligosaccharides (FOS) ntawm Human Gut Microflora. Sci. Rep. 2019, 9, 5473. [CrossRef] [PubMed]
195. Liu, F.; Li, P.; Chen, M.; ib. Luo, Y.; Prabhakar, M.; Zheng, H.; Nws, Y.; Qi, Q.; Ntev, H.; Zhang, YJ; ua al. Fructooligosaccharide (FOS) thiab Galactooligosaccharide (GOS) Ua kom Bifidobacterium tab sis txo qis Butyrate tsim cov kab mob uas tsis zoo Glycemic Metabolism hauv cov tub ntxhais hluas noj qab haus huv. Sci. Rep. 2017, 7, 11789. [CrossRef] [PubMed]
196. Parnell, JA; Raman, M.; Rioux, KP; Reimer, RA Lub Luag Haujlwm Muaj Peev Xwm ntawm Prebiotic Fiber rau Kev Kho Mob thiab Kev Tswj Xyuas Cov Kab Mob Ntshav Qab Zib Fatty Liver thiab Associated Obesity thiab Insulin Resistance. Lub siab Int. 2012, 32, 701–711. [CrossRef] [PubMed]
197. Daubioul, CA; Horsmans, Y.; Lambert, P.; Danis, E.; Delzenne, NM Cov teebmeem ntawm Oligofructose ntawm Glucose thiab Lipid Metabolism hauv Cov Neeg Mob uas Tsis Muaj Cawv Steatohepatitis: Cov txiaj ntsig ntawm Kev Tshawb Fawb. Eur. J. Clin. Nutr. 2005, 59, 723–726. [CrossRef] [PubMed]
198. Fan, J.-G. Cov txiaj ntsig ntawm Lactulose ntawm Kev Tsim Cov Tsiaj Tsiaj Tsiaj Tsiaj Steatohepatitis Model. WJG 2005, 11, 5053. [CrossRef] [PubMed]
199. Matsumoto, K.; Ichimura, M.; Tsawm, K.; Moritoki, Y.; Tsunashima, H.; Omagari, K.; Xav, M.; Yasuda, I.; Miyakawa, H.; Kikuchi, K. Fructo-Oligosaccharides thiab plab hnyuv muaj nuj nqi hauv Methionine-Choline-Deficient Mouse Model ntawm Nonalcoholic Steatohepatitis. PLoS ONE 2017, 12, e0175406. [CrossRef] [PubMed]
200. Ebrahimi-Mameghani, M.; Aliashrafi, S.; Javadzadeh, Y.; AsghariJafarabadi, M. Cov nyhuv ntawm Chlorella Vulgaris Supplementation rau daim siab Enzymes, Serum Glucose, thiab Lipid Profile nyob rau hauv cov neeg mob uas tsis yog-Alcoholic Fatty Liver Disease. Kev Txhawb Kev Noj Qab Haus Huv. Kev xav. 2014. [CrossRef]
201. Javadi, L.; ib. Ghavami, M.; Khoshbaten, M.; Safaiyan, A.; Barzegari, A.; Pourghassem Gargari, B. Cov nyhuv ntawm Probiotic thiab/lossis Prebiotic ntawm Kev Ntsuam Xyuas Siab Ua Haujlwm hauv cov neeg mob uas tsis muaj dej cawv fatty siab: Kev sim ob qhov muag dig muag Randomized. Iran. Liab Crescent. Med. J. 2017, 19. [CrossRef]
202. Vulvic, J.; Juric, A.; Walton, PE; Claus, SP; Tzortzis, G.; Mus rau, RE; Gibson, GR Influence ntawm Galacto-Oligosaccharide Mixture (B-GOS) ntawm Gut Micro.biota, Immune Parameters thiab Metabonomics hauv Cov Neeg Laus. Br. J. Nutr. 2015, 114, 586–595. [CrossRef]
203. Vulvic, J.; Drakoularakou, A.; Yaqoob, P.; Tzortzis, G.; Gibson, GR Modulation ntawm Fecal Microflora Profile thiab Immune Function los ntawm Novel Trans-Galactooligosaccharide Mixture (B-GOS) hauv Cov Neeg Laus Noj Qab Haus Huv. Am. J. Clin. Nutr. 2008, 88, 1438–1446. [CrossRef]
204. Walton, GE; van den Heuvel, EGHM; Kosters, MHW; Rastall, RA; Tug, KM; Gibson, GR A Randomized Crossover Txoj Kev Tshawb Fawb Kev Tshawb Fawb Txog Cov teebmeem ntawm Galacto-Oligosaccharides ntawm Faecal Microbiota hauv cov txiv neej thiab poj niam hnub nyoog tshaj 50 xyoo. Br. J. Nutr. 2012, 107, 1466–1475. [CrossRef]
205. Markowiak, P.; 'Sli˙zewska, K. Cov teebmeem ntawm Probiotics, Prebiotics, thiab Synbiotics on Human Health. Nutrients 2017, 9, 1021. [CrossRef] [PubMed]
206. Malaguarnera, M.; Vacante, M.; Antic, T.; Giordano, M. Chisari, G.; Acquaviva, R. Mastrojeni, S.; Malaguarnera, G.; Mistretta, A.; Li Volti, G.; ua al. Bifidobacterium Longum nrog Fructo-Oligosaccharides nyob rau hauv cov neeg mob uas tsis yog-Alcoholic Steatohepatitis. khawb. Dis. Sci. 2012, 57, 545–553. [CrossRef] [PubMed]
207. Eslamparast, T.; Poustchi, H.; Zamani, F.; Sharafkhah, M. Malekzadeh, R.; Hekmatdoost, A. Synbiotic Supplementation in Nonalcoholic Fatty Liver Disease: A Randomized, Ob-dig muag, Placebo-Controlled Pilot Study. Am. J. Clin. Nutr. 2014, 99, 535–542. [CrossRef] [PubMed]
208. Mofidi, F.; Poustchi, H.; Yari, Z.; Nourinayyer, IB; Merat, S.; Sharafkhah, M. Malekzadeh, R.; Hekmatdoost, A. Synbiotic Supplementation in Lean Patients with Non-Alcoholic Fatty Liver Disease: A Pilot, Randomised, Ob-dig muag, placebo-controlled, Clinical Trial. Br. J. Nutr. 2017, 117, 662–668. [CrossRef] [PubMed]
209. Scorletti, E.; Afolabi, PR; Miles, EA; Smith, DE; Almehmadi, A.; Alshathry, A.; Cov me nyuam, CE; Del Fabbro, S.; Bilson, J.; ib. Moyses, HE; ua al. Synbiotics Hloov Fecal Microbiomes, Tab sis tsis yog daim siab rog lossis Fibrosis, nyob rau hauv kev sim randomized ntawm cov neeg mob uas tsis yog-coholic fatty siab kab mob. Gastroenterology 2020, 158, 1597–1610.e7. [CrossRef]
210. Ferolla, S.; Couto, C.; Costa-Silva, L. Armiliato, G.; Pereira, C.; Martins, F.; Ferrari, M.; ib. Vila, E.; Taus, H.; Cunha, A.; ua al. Cov txiaj ntsig zoo ntawm Synbiotic Supplementation ntawm Hepatic Steatosis thiab Anthropometric Parameters, Tab sis tsis yog ntawm plab permeability nyob rau hauv cov pej xeem nrog Nonalcoholic Steatohepatitis. Nutrients 2016, 8, 397. [CrossRef]
211. Asgharian, A.; Mohammad, V.; Gholi, Z.; Esmaillzade, UA; Feej, A.; Askari, G. Cov nyhuv ntawm Synbiotic Supplementation on Body Composition and Lipid Profile in Patients with NAFLD: Ib Randomized, Ob Chav Dig Muag, Placebo-Controlled Clinical Trial Study. Iran. Liab Crescent. Med. J. 2017, 19. [CrossRef]
212. Asgharian, A.; Askari, G.; Esmailzade, UA; Feej, A.; Mohammadi, V. Cov nyhuv ntawm Symbiotic Supplementation ntawm daim siab Enzymes, c-Reactive Protein thiab Ultrasound Nrhiav nyob rau hauv cov neeg mob uas tsis yog-Alcoholic Fatty Liver Disease: Kev sim tshuaj. Int. J. Prev. Med. 2016, 7, 59. [CrossRef]
213. Björklund, M.; Ouwehand, AC; Forssten, SD; Nikkilä, J.; Thiihonen, K.; Rautonen, N.; Lahtinen, SJ Gut Microbiota ntawm Cov Neeg Laus Noj Qab Haus Huv NSAID Cov Neeg Siv Khoom Xaiv tau raug hloov kho nrog kev tswj hwm ntawm Lactobacillus Acidophilus NCFM thiab Lactitol. Xyoo 2012, 34, 987–999. [CrossRef]
214. Macfarlane, S.; Cleary, S.; Bahrami, IB; Reynolds, N.; Macfarlane, GT Synbiotic Consumption Hloov Cov Metabolism thiab Kev Muaj Peev Xwm ntawm plab Microbiota hauv cov neeg laus thiab hloov cov txheej txheem mob: Ib qho Randomised, Ob-dig muag, Placebo-Controlled Crossover Study. Khoom noj khoom haus. Pharm. 2013, 38, 804–816. [CrossRef]
215. Bartosch, S.; Woodmansey, EJ; Paterson, JCM; McMurdo, MET; Macfarlane, GT Microbiological Effects of Consuming a Synbiotic Containing Bifidobacterium Bifidum, Bifidobacterium Lactis, thiab Oligofructose in Elderly, txiav txim siab los ntawm Real-Time Polymerase Chain Reaction thiab suav cov kab mob siv tau. Clin. Kab mob. Dis. 2005, 40, 28–37. [CrossRef] [PubMed]
216. Juárez-Fernández, M.; Porras, D.; Petrov, P.; Roman-Sagüillo, S.; García-Mediavilla, MV; Soluyanova, P. Martínez-Flórez, S.; González-Gallego, J.; Nistal, E.; Jover, R.; ua al. Kev sib xyaw Synbiotic ntawm Akkermansia Muciniphila thiab Quercetin Ameliorates Thaum Ntxov Kev rog thiab NAFLD los ntawm Gut Microbiota Reshaping thiab Bile Acid Metabolism Modulation. Antioxidants 2021, 10, 2001. [CrossRef]
217. Kim, KO; Gluck, M. Fecal Microbiota Transplantation: Ib qho Kev Hloov Kho ntawm Kev Kho Mob. Clin. Endosc. 2019, 52, 137–143. [CrossRef] [PubMed]
218. Cammarota, G.; Ianiro, G.; Gasbarrini, A. Faecal Microbiota Transplantation nyob rau hauv Clinical Practice. Xyoo 2018, 67, 196.2–197. [CrossRef]
219. Zhou, D.; Pan, Q.; Shen, F.; Cai, H.; Ding, W.; Chen, Y.; Ntxuam, J. Total Fecal Microbiota Transplantation Alleviates High-Fat Diet-Induced Steatohepatitis in Nice of Beneficial Regulation of Gut Microbiota. Sci. Rep. 2017, 7, 1529. [CrossRef]
220. García-Lezana, T.; Raurel, I.; Bravo, M.; ib. Torres-Arauz, M.; Salcedo, MT; Santiago, UA; Schoenenberger, UA; Manichanh, C.; Genescà, J.; Martell, M.; ua al. Restoration of Healthy Intestinal Microbiota Normalizes Portal Hypertension in a Rat Model of Nonalcoholic Steatohepatitis: Lub siab tsis ua haujlwm / Cirrhosis / Portal Hypertension. Hepatology 2018, 67, 1485–1498. [CrossRef]
221. Witjes, JJ; Smits, LP; Pekmez, CT; Prodan, A.; Meijnikman, AS; Troelstra, MA; Bouter, KEC; Herrema, H.; ib. Levin, E.; Holleboom, AG; ua al. Pub Fecal Microbiota Transplantation Hloov Pauv Microbiota thiab Metabolites hauv Cov Neeg Obese nrog Steatohepatitis. Hepatol. Pawg. 2020, 4, 1578–1590. [CrossRef] [PubMed]
222. Craven, L.; Rahman, UA; Nair Parvathy, S.; Beaton, M.; ib. Silverman, J.; Qumosani, K.; Hramiak, I.; Hegele, R.; Zoo, T.; Meddings, J.; ua al. Allogenic Fecal Microbiota Transplantation nyob rau hauv cov neeg mob nrog Nonalcoholic Fatty Liver Disease Txhim kho cov plab hnyuv me me tsis zoo: Ib qho kev sib tw randomized. Am. J. Gastroenterol. 2020, 115, 1055–1065. [CrossRef]
